Abstract
We analyzed previously generated stable monocyte-derived cell line carrying mutation JAK2 V617F. Evaluation of the expression of pro- and antifibrotic factors revealed changes in the production of MMPs and their inhibitors, growth factors, galectin-3, and pentraxin 3 in cells carrying mutation JAK2 in comparison with control non-modified cells.
Keywords:
JAK2 V617F; macrophages; myeloproliferative neoplasms; primary myelofibrosis.
MeSH terms
-
Blood Proteins
-
C-Reactive Protein / genetics
-
C-Reactive Protein / metabolism
-
Cell Communication
-
Coculture Techniques
-
Galectin 3 / genetics
-
Galectin 3 / metabolism
-
Galectins
-
Gene Expression Regulation*
-
Humans
-
Janus Kinase 2 / genetics*
-
Janus Kinase 2 / metabolism
-
Matrix Metalloproteinases / genetics
-
Matrix Metalloproteinases / metabolism
-
Mesenchymal Stem Cells / cytology
-
Mesenchymal Stem Cells / metabolism*
-
Models, Biological
-
Mutation*
-
Primary Cell Culture
-
Primary Myelofibrosis / genetics
-
Primary Myelofibrosis / metabolism
-
Primary Myelofibrosis / pathology
-
Protein Isoforms / genetics
-
Protein Isoforms / metabolism
-
Serum Amyloid P-Component / genetics
-
Serum Amyloid P-Component / metabolism
-
Signal Transduction
-
THP-1 Cells
-
Tissue Inhibitor of Metalloproteinases / genetics
-
Tissue Inhibitor of Metalloproteinases / metabolism
Substances
-
Blood Proteins
-
Galectin 3
-
Galectins
-
LGALS3 protein, human
-
Protein Isoforms
-
Serum Amyloid P-Component
-
Tissue Inhibitor of Metalloproteinases
-
PTX3 protein
-
C-Reactive Protein
-
JAK2 protein, human
-
Janus Kinase 2
-
Matrix Metalloproteinases